VXRTのニュース
Vaxart signs pact with hVIVO to help develop oral COVID-19 vaccine pill 2022/06/30 13:15:55 Seeking Alpha
Vaxart (VXRT) said on Thursday it had entered an agreement with hVIVO Services Limited, a subsidiary of London-based firm Open Orphan. Under the agreement, hVIVO will conduct a study…
Open Orphan’s hVIVO developing the world’s first Omicron human challenge model 2022/06/30 06:23:09 Directors Talk
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, is developing the world’s first Omicron human challenge model. hVIVO has signed an agreement with Vaxart Inc., (NASDAQ: VXRT) to develop the model […]
Open Orphan hVIVO to develop the world’s first Omicron human challenge model 2022/06/30 06:22:59 DirectorsTalk
Vaxart becomes the first client of the programme to test its oral COVID-19 vaccine candidate Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, is developing the world''s first Omicron human challenge model. hVIVO has signed an agreement with Vaxart Inc. , (NASDAQ: VXRT) to develop the model with the intent to conduct a subsequent Omicron human challenge study in 2023 to test the efficacy of Vaxart''s oral vaccine candidate, VXA-CoV2-1. To develop the model, hVIVO will manufacture a new SARS-CoV-2 (COVID-19) challenge agent based on the Omicron variant. The Good Manufacturing Practice compliant virus manufacturing activities will commence immediately and are expected to complete by Q4 2022. Following manufacture of the challenge agent, the Company intends to conduct a characterisation study.
Vaxart Inc. (VXRT): What Makes The Stock Attractive? 2022/06/29 11:30:00 Marketing Sentinel
Vaxart Inc. (NASDAQ:VXRT) has a beta value of 0.69 and has seen 1.93 million shares traded in the last trading session. The company, currently valued at $429.57M, closed the last trade at $3.48 per share which meant it lost -$0.17 on the day or -4.66% during that session. The VXRT stock price is -196.84% off … Vaxart Inc. (VXRT): What Makes The Stock Attractive? Read More »
Vaxart: A Unique Vaccine Concern (NASDAQ:VXRT) 2022/06/14 19:40:48 Seeking Alpha
Vaxart is developing several vaccine candidates targeting large potential markets via an oral pill that can be stored at room temperature. See more on VXRT here.
Vaxart Stock: Awaiting Platform Validation for the Bull-Case to Kick In 2022/03/07 19:34:39 TipRanks
Vaxart (VXRT) shot to prominence in the early days of the pandemic, as one of the small vaccine makers taking the fight to Covid-19. But that was a while ago
Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform 2022/02/26 08:24:19 Seeking Alpha
Vaxart GAAP EPS of -$0.17 misses by $0.01, revenue of $0.07M misses by $0.11M 2022/02/24 22:30:34 Seeking Alpha
Vaxart press release (NASDAQ:VXRT): Q4 GAAP EPS of -$0.17 misses by $0.01.Revenue of $0.07M (-80.6% Y/Y) misses by $0.11M.
Vaxart shares fall following data on COVID vaccine 2022/02/24 14:20:44 Seeking Alpha
Shares of Vaxart (VXRT) are down 10% in premarket trading after releasing mid-stage data on its oral COVID-19 vaccine candidate.
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart 2022/02/17 15:07:07 Benzinga
Macy''s Inc (NYSE: M ) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors. Since February 2021, Macy’s stock’s one-year return has outperformed several of the world’s most popular vaccine stocks: Moderna Inc (NASDAQ: MRNA ), Pfizer Inc. (NYSE: PFE ), BioNTech SE - ADR (NASDAQ: BNTX ), Novavax, Inc. (NASDAQ: … Full story available on Benzinga.com
Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average of $7.62 2021/12/19 12:22:41 Dakota Financial News
Vaxart, Inc. (NASDAQ:VXRT)s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $7.62 and traded as low as $6.41. Vaxart shares last traded at $7.20, with a volume of 9,325,846 shares trading hands. A number of equities research analysts []
Vaxart Stock Crosses 2 Key Levels Friday: What''s Next? 2021/12/17 19:42:52 Business Insider Markets
Vaxart Inc. (NASDAQ: VXRT ) shares were trading higher Friday after the company plans to test the cross-reactivity of its…
Vaxart shares rise 8% on promise of oral COVID vaccine against Omicron 2021/12/17 19:27:11 Seeking Alpha
A Sharp Uptick in Infections Reignites Fears of New Restrictions 2021/12/17 14:00:00 Benzinga
NEW YORK , Dec. 17, 2021 /PRNewswire/ -- The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As an example, test positivity rates in New York City have doubled in just three days, Dr. Jay Varma , a top health advisor to Mayor Bill de Blasio , tweeted Thursday. According to data provided by the CDC on Wednesday, New York and New Jersey are the two states with the most rapid spread of the Omicron variant. To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC''s national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. In the meantime, restrictions for private businesses have become more strict. Todos Medical Ltd. (OTC: TOMDF ), Pfizer Inc. (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Vaxart, Inc. (NASDAQ: VXRT ) As a result of the most recent surge, schools like New York University and Cornell University have canceled in-person events and shifted finals online.